GCM
VRTX icon

Glaxis Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Glaxis Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,000
Closed -$760K – 36
2017
Q3 		$760K Buy
+5,000
New +$753K 1.16% 16
2013
Q4 		– Sell
-10,600
Closed -$804K – 50
2013
Q3 		$804K Buy
+10,600
New +$843K 1.62% 25

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Glaxis Capital Management's VRTX Position: Q4 2017 in Review

Glaxis Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2017, closing a stake of 5,000 shares — an estimated $760K sold.

Glaxis Capital Management first reported a position in VRTX in Q3 2013 and held it in 2 quarters. The position peaked at $804K in Q3 2013. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

  • Glaxis Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Glaxis Capital Management sold 5,000 Vertex Pharmaceuticals shares in Q4 2017, an estimated $760K.
  • Glaxis Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • Glaxis Capital Management's Vertex Pharmaceuticals position peaked at $804K in Q3 2013.
  • 644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on Glaxis Capital Management's 13F filing for Q4 2017, filed 6 Feb 2018.